NCT05874414 2026-01-22Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated CholangiocarcinomaGenfitPhase 1/2 Recruiting74 enrolled
NCT04294160 2025-12-24A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal CancerNovartisPhase 1 Terminated122 enrolled
NCT02034110 2023-08-21Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare CancersNovartisPhase 2 Completed206 enrolled 40 charts 2 FDA
NCT02900664 2022-03-29A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)NovartisPhase 1 Completed283 enrolled
NCT02703571 2020-12-21Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid TumorsNovartisPhase 1 Terminated95 enrolled
NCT01155453 2020-12-09A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor PatientsNovartisPhase 1 Completed113 enrolled
NCT02538627 2017-09-05Phase 1 Combination Study of MM-151 With MM-121, MM-141, or TrametinibMerrimack PharmaceuticalsPhase 1 Terminated5 enrolled
NCT01943864 2017-05-31A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract CancersGlaxoSmithKlinePhase 2 Completed20 enrolled 27 charts